Merrill rates OSI at buy

OSI Pharmaceuticals, Inc. was weak on Tarceva sales and on concern that new clinical data for Avastin as well as for Erbitux in pancreatic cancer could hurt future growth of the product. Merrill recommends looking through near-term concerns and focusing on Tarceva's long-term potential in second-line lung cancer and future price increases. First-quarter 2006 Tarceva U.S. sales were $93 million, above consensus of $91 million. Shares of the Melville, N.Y., pharmaceutical company were down $0.32, or 1.18%, at $26.79 on volume of 1,484,326 shares versus the three-month running average of 1,506,040 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.